Moderna uncloaks 'profound' immune-evading mRNA therapeutic platform

Moderna Therapeutics has raised an impressive $40 million-plus in its first 18 months to fund technology that represents a profound change from established biological manufacturing - messenger RNA (mRNA) injected into the body and taken up by cells whose ribosomes then use the mRNA to produce therapeutic intra-cellular or secreted proteins.